Cargando…
Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform
SIMPLE SUMMARY: High-grade serous ovarian cancer is a fatal disease typically detected at an advanced stage when options for effective treatment are significantly limited. The lack of a screening modality to identify ovarian cancer in its early stage continues to be a major impediment in the managem...
Autores principales: | González, Germán, Lakatos, Kornél, Hoballah, Jawad, Fritz-Klaus, Roberta, Al-Johani, Lojain, Brooker, Jeff, Jeong, Sinyoung, Evans, Conor L., Krauledat, Petra, Cramer, Daniel W., Hoffman, Robert A., Hansen, W. Peter, Patankar, Manish S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123299/ https://www.ncbi.nlm.nih.gov/pubmed/33922973 http://dx.doi.org/10.3390/cancers13092072 |
Ejemplares similares
-
Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer
por: Lakatos, Kornél, et al.
Publicado: (2022) -
HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy
por: Xiang, Xinran, et al.
Publicado: (2011) -
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
por: Felder, Mildred, et al.
Publicado: (2014) -
Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies
por: Goodell, Cara AR, et al.
Publicado: (2009) -
Generation of diverse neuronal subtypes in cloned populations of stem-like cells
por: Varga, Balázs V, et al.
Publicado: (2008)